Article
A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
3 Nov 2022
Abstract excerpt
Improved vaccines and antiviral agents that provide better, broader protection against seasonal and emerging influenza viruses are needed. The viral surface glycoprotein hemagglutinin (HA) is a primary target for the development of universal influenza vaccines and therapeutic antibodies. The other major surface antigen, neuraminidase (NA), has been less well studied as a potential target and fewer broadly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
